New Mountain Capital completed the acquisition of Natrol from Aurobindo Pharma for £421m.

New Mountain Capital, a New York-based investment firm, completed the acquisition of Natrol, a vitamins, minerals and supplements brand, from Aurobindo Pharma, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, for £421m. “Throughout its history, Natrol has stood for the highest quality products designed to drive positive outcomes and enhance quality of life for its users. We thank Aurobindo for their stewardship of Natrol over the last six years, and we look forward to working closely with the management teams at Natrol and Jarrow Formulas to build upon Natrol’s strong momentum and drive continued growth and market-leading innovation,” Andre Moura, New Mountain Capital Managing Director.